Comparative Assessment of the Different American College of Rheumatology/European League Against Rheumatism Remission Definitions for Rheumatoid Arthritis for Their Use as Clinical Trial End Points.

about

Drug-free remission: the goal of the future in management of patients with rheumatoid arthritis.Clinical, Imaging, and Pathological Suppression of Synovitis in Rheumatoid Arthritis: Is the Disease Curable?

P2860

Q54967304-915B7D19-C332-4EEB-BFB1-D927B1EDEF8F Q55191136-227E920B-A1BA-4BE2-9B90-91E2F7905616

P2860

Comparative Assessment of the Different American College of Rheumatology/European League Against Rheumatism Remission Definitions for Rheumatoid Arthritis for Their Use as Clinical Trial End Points.

Item

http://www.wikidata.org/entity/Q38815347

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Comparative Assessment of the ...... as Clinical Trial End Points.

@en

type

Item

label

Comparative Assessment of the ...... as Clinical Trial End Points.

@en

prefLabel

Comparative Assessment of the ...... as Clinical Trial End Points.

@en

P1476

Comparative Assessment of the ...... as Clinical Trial End Points.

@en

P2093

Daniel Aletaha

http://www.w3.org/2001/XMLSchema#string

Elizabeth Hsia

http://www.w3.org/2001/XMLSchema#string

Michael E Mack

http://www.w3.org/2001/XMLSchema#string

P2860

Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score.

2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update

The perception of rheumatoid arthritis core set measures by rheumatologists. Results of a survey.

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group.

Joint damage in rheumatoid arthritis progresses in remission according to the Disease Activity Score in 28 joints and is driven by residual swollen joints.

Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis.

Treating rheumatoid arthritis to target: recommendations of an international task force.

Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial.

Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study.

P304

518-528

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/ART.39945

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27696724

http://www.w3.org/2001/XMLSchema#string

Comparative Assessment of the Different American College of Rheumatology/European League Against Rheumatism Remission Definitions for Rheumatoid Arthritis for Their Use as Clinical Trial End Points.

about

P2860

P2860

Comparative Assessment of the Different American College of Rheumatology/European League Against Rheumatism Remission Definitions for Rheumatoid Arthritis for Their Use as Clinical Trial End Points.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698